Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bial - Portela & Ca SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10823
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ポルトガル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bial – Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants and anti-anemics, among others. Its products find its application in various therapeutic areas such as antibiotic therapy, cardiovascular diseases, central nervous system, immunotherapy, musculoskeletal system, and respiratory disease. BIAL offers services such as research, development, scientific research, integrity rigor and administration of the RDI management system, among others. The company has its presence in Angola, Cote d’Ivoire, Germany, Italy, Mozambique, Panama, Poland, Spain, Switzerland, and the UK. BIAL is headquartered in Porto, Portugal.

Bial – Portela & Ca SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Bial – Portela Acquires Business Unit from Grupo Juste 10
Partnerships 11
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 11
Licensing Agreements 12
WhanIn Pharma Enters into Licensing Agreement with Bial – Portela 12
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial – Portela 13
Neurocrine Biosciences Enters into Licensing Agreement with Bial 14
BIAL Enters into Licensing Agreement with Helsinn 15
Bial Enters into Licensing Agreement with Moksha8 Pharma for Eslicarbazepine Acetate 16
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 17
Acquisition 18
Roxall Medizin to Acquire Bial-Aristegui from Bial – Portela & Ca 18
Bial – Portela & Ca SA – Key Competitors 19
Bial – Portela & Ca SA – Key Employees 20
Bial – Portela & Ca SA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Key Facts 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial - Portela & Ca SA, Deals By Therapy Area, 2012 to YTD 2018 8
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bial - Portela Acquires Business Unit from Grupo Juste 10
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 11
WhanIn Pharma Enters into Licensing Agreement with Bial - Portela 12
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial - Portela 13
Neurocrine Biosciences Enters into Licensing Agreement with Bial 14
BIAL Enters into Licensing Agreement with Helsinn 15
Bial Enters into Licensing Agreement with Moksha8 Pharma for Eslicarbazepine Acetate 16
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 17
Roxall Medizin to Acquire Bial-Aristegui from Bial - Portela & Ca 18
Bial - Portela & Ca SA, Key Competitors 19
Bial - Portela & Ca SA, Key Employees 20
Bial - Portela & Ca SA, Subsidiaries 21

List of Figures
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electricity Generating Authority of Thailand:企業の戦略・SWOT・財務分析
    Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report Summary Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Guangzhou Wondfo Biotech Co Ltd (300482):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that develops, manufactures and supplies rapid diagnostic reagents and related equipment. Its products include rapid quantitative test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo also of …
  • Rosoboronexport:企業の戦略・SWOT・財務情報
    Rosoboronexport - Strategy, SWOT and Corporate Finance Report Summary Rosoboronexport - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Lay Hong Berhad (LAYHONG):企業の財務・戦略的SWOT分析
    Lay Hong Berhad (LAYHONG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Brown & Brown Inc:企業の戦略・SWOT・財務分析
    Brown & Brown Inc - Strategy, SWOT and Corporate Finance Report Summary Brown & Brown Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Penn Virginia Corporation (PVAC)-石油・ガス分野:企業M&A・提携分析
    Summary Penn Virginia Corporation (Penn Virginia) is an independent oil and gas company. It explores, develops, and produces crude oil, Natural gas liquids (NGL), and natural gas. The company carries out its operations in various domestic onshore regions of the US, primarily in the Eagle Ford Shale …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務分析
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Newpark Resources Inc (NR):石油・ガス:M&Aディール及び事業提携情報
    Summary Newpark Resources Inc (Newpark) offers fluid systems and services to oil and gas industry. The company offers drilling fluid products, solutions and services supporting directional, horizontal and deep water drilling projects. It grinds barite, which is used as a raw material in drilling flu …
  • Polski Koncern Naftowy ORLEN SA:企業の戦略・SWOT・財務情報
    Polski Koncern Naftowy ORLEN SA - Strategy, SWOT and Corporate Finance Report Summary Polski Koncern Naftowy ORLEN SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Bio-Modeling Systems SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Bio-Modeling Systems SAS (BM Systems) is a biotechnology company that discovers and develops novel diagnostic, therapeutic and prevention solutions. The company owns an operational mechanisms-based medicine platform known as computer-assisted deductive integration (CADI), which is used in th …
  • Ujaas Energy Ltd (UJAAS):企業の財務・戦略的SWOT分析
    Summary Ujaas Energy Ltd (Ujaas) is a renewable energy company that offers solar energy development products and services. The company provides products such as home products, park products, transformers, and others. It offers transformers products such as power transformer, convertor transformers, …
  • CITIC Securities Company Limited:戦略・SWOT・企業財務分析
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Eckert & Ziegler Strahlen- und Medizintechnik AG (Eckert & Ziegler) is a medical device company that offers isotope technology products. The company offers radiation therapy, isotope and radio-pharma products. It provides radiation therapy products for Brachytherapy, a minimally invasive pro …
  • Nihon Kohden Corp (6849):企業の財務・戦略的SWOT分析
    Nihon Kohden Corp (6849) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Living Cell Technologies Ltd (LCT):企業の財務・戦略的SWOT分析
    Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Traverse Energy Ltd (TVL):石油・ガス:M&Aディール及び事業提携情報
    Summary Traverse Energy Ltd (Traverse Energy), formerly Firstland Energy Ltd is an oil and gas company that explores, produces, and develops petroleum and natural gas assets. The company's products include crude oil, natural gas, petroleum products, and associated liquids, among others. It explores …
  • China Metallurgical Group Corp (1618):企業の財務・戦略的SWOT分析
    China Metallurgical Group Corp (1618) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Rosneft Oil Co (ROSN):石油・ガス:M&Aディール及び事業提携情報
    Summary Rosneft Oil Company (Rosneft) is a vertically integrated oil and gas company that explores for, develops and produces crude oil, natural gas and condensates; and refines, markets and distributes petroleum products and petrochemicals. It has exploration assets across Western Siberia, Eastern …
  • CONSOL Energy Inc.:企業のM&A・事業提携・投資動向
    CONSOL Energy Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CONSOL Energy Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • BioSolar Inc (BSRC):企業の財務・戦略的SWOT分析
    Summary BioSolar Inc (BioSolar) is an alternative energy technology company that develops storage capacity products. The company develops technology to produce bio-based materials from renewable sources. BioSolar products include biosolar back-sheets, biosolar thin film substrate, biosolar super-str …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆